• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

Global Alliance for the Treatment of Chagas Disease: Thinking About the Patients

3 Apr 2014

Sylvia Gold

Viewpoint by

Silvia Gold, President, Mundo Sano Foundation

American Trypanosomiasis, more commonly known as Chagas disease, no longer reflects the geographical scope of the disease. Today, Chagas disease affects people around the world. It is hard to imagine that a disease, discovered over a century ago, which today can be easily diagnosed and for which effective treatment exists, continues to be a problem of severe health impact.

Much has been accomplished in recent years, and progress has been achieved in reducing the appearance of new cases. Extensive regions have been able to rid themselves of vector-borne transmission, while others have made great improvements. Blood banks provide a better warrantee for the supply of tested blood, reducing transmission through blood transfusions. The same can be said about organ transplants.

Nevertheless, there is a major deficit.  It is estimated that there are more than 8 million affected and less than 1% treated. There are also a continuous number of newborns who are not being diagnosed with the infection and, consequently, are not getting the medical attention they need.

Currently, the availability of benznidazole, the firstline treatment for Chagas disease, is assured. The effectiveness of the treatment in children is around 90% and there is growing evidence of the benefits the drug for chronic patients. Countries like Argentina, that have updated their protocols to address the disease, suggest treatment to all infected patients.

One of the great challenges is the lack of general practitioners’ awareness on how to fully assist people with Chagas disease. In order to obtain better results, it is important that the disease be given priority in health policies, that the diagnostic methods and drugs are available, and that health systems, especially from the first referral level, are in a position to accept patients.

This great liability is what drove key organizations to create the Global Chagas Disease Coalition to join forces, together with the work carried out by the World Health Organization and the Pan American Health Organization on cooperation and awareness-raising, with the help of national programs in order to improve the situation. Faced with this complex reality, we believe it is necessary to work collectively.

In early March, in Barcelona, Spain, key experts from endemic country governments, pharmaceutical companies and product developers, researchers, and most importantly patient associations came together. But, in order to achieve greater progress, we need more people to join in.

We invite everyone who wants to take part, with their knowledge and commitment, to connect efforts. We cannot afford to lose time: 99 % of the people who are affected still have no access to treatment and cannot wait any longer. It is time to take action.

Dr Silvia Gold
President, Mundo Sano Foundation

The following organizations form the Chagas Coalition: Mundo Sano Foundation, Global Health Institute (ISGlobal), Sabin Vaccine Institute, Drugs for Neglected Diseases initiative (DNDi), the Colectivo de Estudios Aplicados y Desarrollo Social (CEADES) with the support of Doctors Without Borders (MSF), the International Federation of People Affected by Chagas Disease (FINDECHAGAS) and theHealth Institute of the Carlos Slim Foundation. 

Chagas disease

Read, watch, share

Loading...
News
15 Sep 2026

New DNDi report: Implementing Article 9.5 of the WHO Pandemic Agreement – building on current policy and practice for publicly funded R&D

Hand with lap glove holding a sample with transparent liquid
Publications
8 Sep 2026

Implementing Article 9.5 of the WHO Pandemic Agreement

Stories
27 Aug 2026

Drug discovery explained: Moonshot: open science to prepare for pandemics?

Pictures of patients waiting at the Mycetoma Research Center in Sudan
Stories
20 Aug 2026

Mycetoma at 10: What recognition made possible

Nature Africa logo
Viewpoints
3 Aug 2026

A new chapter for African medical innovation

Nature Africa
Viewpoints
30 Jul 2026

Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases

Stat News
Leishmaniasis patient Monica Lomoler carrying a bunch of firewood
Press releases
29 Jul 2026

WHO recommends new, better and safer treatment regimens for leishmaniasis

Press releases
27 Jul 2026

DNDi leadership to change in 2027

VIEW ALL

Help neglected patients

To date, we have delivered seventeen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license